Conference Call on 25 August 2021, 10.00 a.m. CEST presenting half-year results

Korneuburg, Austria, 13 August 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, will provide an update on half-year results 2021 on 25 August 2021 and is pleased to invite you to an international conference call (held in English language). The conference call is scheduled for 10.00 a.m. CEST (8.00 a.m. GMT). Your dialogue partners will be Dr. Andreas Grassauer, CEO, and Pascal Schmidt, CFO.

Pre-registration:

Participants may pre-register and will receive dedicated dial-in details to access the call easily and quickly:

https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=839 6570&linkSecurityString=e236e9e80

Logging in to the call:

Once registered (see above), please use the information provided in the confirmation email. We recommend dialing in a few minutes prior to the call.

Concurrent presentation:

Slide Show (C-Meeting) Participants' Link: https://www.c-meeting.com/web3/join/MLD3PK2LN4AYV8

The Marinomed presentation window will open at the beginning of the conference. The webcast does not support audio (please follow the instructions above for audio).

The presentation can be downloaded c. 15 minutes before the conference call from the Company's website: https://www.marinomed.com/en/investors/publications

The press release on the half-year results 2021 will be published at 7.45 a.m. CEST / 5.45 a.m. GMT and will be available in the news section of the Company's website: https://www.marinomed.com/en/news

If you have any further questions, please do not hesitate to contact:

Pascal Schmidt Chief Financial Officer, Marinomed Biotech AG Hovengasse 25, 2100 Korneuburg, Austria

E-Mail: <u>ir@marinomed.com</u> Tel.: +43 2262 90300

International Media and IR Contact

MC Services AG Dr. Brigitte Keller, Julia Hofmann

T +49 89 210228 0 **UK:** Shaun Brown M: +44 7867 515 918

E-mail: marinomed@mc-services.eu

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.